BioAge discontinues mid-stage trial of obesity drug
06/12/2024 21:43
Dec 6 (Reuters) - BioAge Labs BIOA.O said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly's LLY.N tirzepatide for the treatment of obesity. (Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on BioAge Labs
See all newsBrief: Bioage Labs Announces First Participant Dosed In Quell-Dme, A Phase 2 Trial Of Bge-102, A Novel Oral Nlrp3 Inhibitor, In Diabetic Macular Edema
BioAge Labs, Inc. reports results for the quarter ended June 30 - Earnings Summary
BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaboration
BioAge Labs full-year collaboration revenue beats estimates
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP